Intravenous difelikefalin for the treatment of hemodialysis pruritus

References

• Hashimoto T, Yosipovitch G. Itching as a systemic disease. J Allergy Clin Immunol. 2019;144(2):375–380. doi:10.1016/j.jaci.2019.04.005
   PubMed Web of Science ®Google Scholar
• Kim D, Pollock C. Epidemiology and burden of chronic kidney disease-associated pruritus. Clin Kidney J. 2021;14(Suppl 3):i1–i7. doi:10.1093/ckj/sfab142
   PubMedGoogle Scholar
• Pisoni RL, Wikström B, Elder SJ, et al. Pruritus in haemodialysis patients: international results from the dialysis outcomes and practice patterns study (DOPPS). Nephrol Dial Transplant. 2006;21(12):3495–3505. doi: 10.1093/ndt/gfl461
   PubMed Web of Science ®Google Scholar
• Sukul N, Karaboyas A, Csomor PA, et al. Self-reported pruritus and clinical, dialysis-related, and patient-reported Outcomes in hemodialysis patients. Kidney Med. 2020;3(1):42–53.e1. doi: 10.1016/j.xkme.2020.08.011
   PubMedGoogle Scholar
• Rayner HC, Larkina M, Wang M, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol. 2017;12(12):2000–2007. doi: 10.2215/CJN.03280317
   PubMed Web of Science ®Google Scholar
• Mathur VS, Lindberg J, Germain M, et al. A longitudinal study of uremic pruritus in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(8):1410–1419. doi: 10.2215/CJN.00100110
   PubMed Web of Science ®Google Scholar
• Lopes GB, Nogueira FC, de Souza MR, et al. Assessment of the psychological burden associated with pruritus in hemodialysis patients using the kidney disease quality of life short form. Qual Life Res. 2012;21(4):603–612. doi: 10.1007/s11136-011-9964-x
   PubMed Web of Science ®Google Scholar
• Tessari G, Dalle Vedove C, Loschiavo C, et al. The impact of pruritus on the quality of life of patients undergoing dialysis: a single centre cohort study. J Nephrol. 2009;22(2):241–248.
   PubMed Web of Science ®Google Scholar
• Weiss M, Mettang T, Tschulena U, et al. Health-related quality of life in haemodialysis patients suffering from chronic itch: results from GEHIS (German epidemiology haemodialysis itch study). Qual Life Res. 2016;25(12):3097–3106. doi:10.1007/s11136-016-1340-4
   PubMed Web of Science ®Google Scholar
• Fugal J, SM S. Difelikefalin: a New κ-opioid receptor agonist for the treatment of hemodialysis-dependent chronic kidney disease-associated pruritus. Ann Pharmacother. 2023;57(4):480–488. doi:10.1177/10600280221115889
   PubMed Web of Science ®Google Scholar
• Mettang T, Kremer AE. Uremic pruritus. Kidney Int. 2015;87(4):685–691. doi:10.1038/ki.2013.454
   PubMed Web of Science ®Google Scholar
• Wala-Zielińska K, Świerczyńska-Mróz K, Krajewski PK, et al. Endogenous opioid imbalance as a potential factor involved in the pathogenesis of chronic kidney disease-associated pruritus in dialysis patients. J Clin Med. 2023;12(7):2474. doi: 10.3390/jcm12072474
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Rosen JD, Hashimoto T. Itch: from mechanism to (novel) therapeutic approaches. J Allergy Clin Immunol. 2018 Nov;142(5):1375–1390. doi: 10.1016/j.jaci.2018.09.005
   PubMed Web of Science ®Google Scholar
• Kumagai H, Ebata T, Takamori K, et al. Effect of a novel kappa-receptor agonist, nalfurafine hydrochloride, on severe itch in 337 haemodialysis patients: a phase III, randomized, double-blind, placebo-controlled study. Nephrol Dial Transplant. 2010;25(4):1251–1257. doi: 10.1093/ndt/gfp588
   PubMed Web of Science ®Google Scholar
• Fishbane S, Jamal A, Munera C, et al. A phase 3 trial of difelikefalin in hemodialysis patients with pruritus. N Engl J Med. 2020;382(3):222–232. doi: 10.1056/NEJMoa1912770
   PubMed Web of Science ®Google Scholar
• Meariman JK, Sutphen JC, Gao J, et al. Difelikefalin, a peripherally restricted KOR (kappa opioid receptor) agonist, produces diuresis through a central KOR pathway. Pharmacol Res. 2022;185:106470. doi: 10.1016/j.phrs.2022.106470
   PubMed Web of Science ®Google Scholar
• Narita I, Tsubakihara Y, Uchiyama T, et al. Efficacy and safety of difelikefalin in Japanese patients with moderate to severe pruritus receiving hemodialysis: a randomized clinical trial. JAMA Netw Open. 2022;5(5):e2210339. doi: 10.1001/jamanetworkopen.2022.10339
   PubMed Web of Science ®Google Scholar
• Fishbane S, Mathur V, Germain MJ, et al. Randomized controlled trial of difelikefalin for chronic pruritus in hemodialysis patients. Kidney Int Rep. 2020;5(5):600–610. doi: 10.1016/j.ekir.2020.01.006
   PubMed Web of Science ®Google Scholar
• Fishbane S, Wen W, Munera C, et al. Safety and tolerability of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis from the phase 3 clinical trial program. Kidney Med. 2022;4(8):100513. doi: 10.1016/j.xkme.2022.100513
   PubMedGoogle Scholar
• Highlights of prescribing information KORSUVATM (difelikefalin) injection, for intravenous use. [cited2023 Jun 30]. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2021/214916s000lbl.pdf
   Google Scholar
• Stark JG, Noonan PK, Spencer RH, et al. Pharmacokinetics, metabolism, and excretion of intravenous [14C]Difelikefalin in healthy subjects and subjects on hemodialysis. Clin Pharmacokinet. 2023;62(9):1231–1241. doi:10.1007/s40262-023-01262-2
   PubMedGoogle Scholar
• Product monograph including patient medication information- KORSUVA. [cited 2023 Sep 14]. Available from: https://otsukacanada.com/product_monographs/KORSUVA_EN.pdf.
   Google Scholar
• Assessment report - Kapruvia. European Medicines Agency. [cited 2023 Jun 30]. Available from: www.ema.europa.eu/en/documents/assessment-report/kapruvia-epar-public-assessment-report_en.pdf.
   Google Scholar
• Annex I Summary of product characteristics - kapruvia. European Medicines Agency. [cited 2023 Jun 30]. Available from: www.ema.europa.eu/en/documents/product-information/kapruvia-epar-product-information_en.pdf
   Google Scholar
• Vernon MK, Swett LL, Speck RM, et al. Psychometric validation and meaningful change thresholds of the Worst Itching intensity numerical Rating scale for assessing itch in patients with chronic kidney disease-associated pruritus. J Patient Rep Outcomes. 2021;5(1):134. doi: 10.1186/s41687-021-00404-z
   PubMedGoogle Scholar
• Vernon M, Ständer S, Munera C, et al. Clinically meaningful change in itch intensity scores: an evaluation in patients with chronic kidney disease-associated pruritus. J Am Acad Dermatol. 2021;84(4):1132–1134. doi: 10.1016/j.jaad.2020.06.991
   PubMed Web of Science ®Google Scholar
• Topf J, Wooldridge T, McCafferty K, et al. Efficacy of difelikefalin for the treatment of moderate to severe pruritus in hemodialysis patients: pooled analysis of KALM-1 and KALM-2 phase 3 studies. Kidney Med. 2022;4(8):100512. doi: 10.1016/j.xkme.2022.100512
   PubMedGoogle Scholar
• Wala K, Szepietowski JC. Difelikefalin in the treatment of chronic kidney disease-associated pruritus: a systematic review. Pharmaceuticals (Basel). 2022;15(8):934. doi:10.3390/ph15080934
   PubMedGoogle Scholar
• Spencer RH, Munera C, Shram MJ, et al. Assessment of the physical dependence potential of difelikefalin: randomized placebo-controlled study in patients receiving hemodialysis. Clin Transl Sci. 2023;16(9):1559–1568. doi: 10.1111/cts.13538
   PubMed Web of Science ®Google Scholar
• Viscusi ER, Torjman MC, Munera CL, et al. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: a randomized, double-blind, placebo-controlled trial. Clin Transl Sci. 2021;14(5):1886–1893. doi: 10.1111/cts.13042
   PubMed Web of Science ®Google Scholar
• Weiner DE, Vervloet MG, Walpen S, et al. Safety and effectiveness of difelikefalin in patients with moderate-to-severe pruritus undergoing hemodialysis: an open-label, multicenter study. Kidney Med. 2022;4(10):100542. doi: 10.1016/j.xkme.2022.100542
   PubMedGoogle Scholar
• Kraft L, Schanz M, Schricker S, et al. The first real-world experience of IV difelikefalin to treat chronic kidney disease-associated pruritus in haemodialysis patients. J Eur Acad Dermatol Venereol. 2023;37(8). doi: 10.1111/jdv.19105
   Web of Science ®Google Scholar
• Manenti L, Leuci E. Do you feel itchy? A guide towards diagnosis and measurement of chronic kidney disease-associated pruritus in dialysis patients. Clin Kidney J. 2021;14(Suppl 3):i8–i15. doi:10.1093/ckj/sfab143
   PubMedGoogle Scholar
• Yosipovitch G, Awad A, Spencer RH, et al. A phase 2 study of oral difelikefalin in subjects with chronic kidney disease and moderate-to-severe pruritus. J Am Acad Dermatol. 2023;89(2):261–268. doi: 10.1016/j.jaad.2023.03.051
   PubMed Web of Science ®Google Scholar
• Thokala P, Hnynn Si PE, Hernandez Alava M, et al. Cost effectiveness of difelikefalin compared to standard care for treating chronic kidney disease associated pruritus (CKD-aP) in people with kidney failure receiving Haemodialysis. PharmacoEconomics. 2023;41(4):457–466. doi: 10.1007/s40273-022-01237-4
   PubMed Web of Science ®Google Scholar